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A. Asrian, A. Tzakis, S. Todo, J. Fung, and T. Starzl 
PK 506 is currently used as the primary immunosup-pressive drug in several small bowel transplant (SBT) 
recipients.1.2 The pharmacokinetics of FK 506 has been 
previously reported in orthotopic liver transplant (OLT) 
patients.3 The kinetics and dosage of FK 506 have been 
compared to that of cyclosporine (Cy A)4 and differences in 
the dosage requirements of FK 506 have been reported in 
adults and children.' We have previously reported the IV 
and oral kinetics of FK 506 in five SBT recipients.6 The 
aim of the present study is to further evaluate the kinetic 
parameters and dosage of FK 506 in pediatric and adult 
SBT recipients in comparison with OLT recipients. 
MATERIALS AND METHODS 
Between May 1990 and December 1992. 34 patients received 
cadaveric SBT with or without liver transplantation. Four patients 
who died and one patient who was retransplanted in less than 12 
months were excluded from the study. The study group consisted 
of 16 adults (mean age 30.2 :!: 8.8 years). 7 men and 9 women. and 
13 children (mean age 2.9 :!: 2.6 years). 5 boys and 8 girls. Oral 
dose and trough levels of FK 506 were compared with 20 adults 
and 20 pediatric OLT recipients. In addition. 21 (11 adults. 10 
children) pharmacokinetic studies were carried out during one 
dosing interval after oral administration of FK 506. Seventeen 
kinetic studies were performed with IV FK 506 (10 continuous 
infusions. 7 4-hour infusions: 24 hour kinetic studies). MUltiple 
blood samples were obtained and plasma was separated at 37°C 
and analyzed for FK 506 concentrations by enzyme-linked immu· 
nosorbent assay (ELlSAl.7•K 
RESULTS 
IV Kinetics 
The plasma concentration vs time profile after IV and oral 
administration is shown in Fig I. The mean plasma clear-
ance ofFK 506 was 2[,7 :!: 9.0 mUminlkg in adults (n = 6) 
and 32.1 ± 12.7 mUminlkg in children (n = 11). Its half-life 
was similar (13.7 hours) in seven patients (four adults and 
three children). 
Oral Kinetics 
Following an oral dose of FK 506. the mean bioavailability 
was 19.0 :!: 8.7'7c in adults and 24.5 :!: 19.4lf( in children. 
The mean time to peak was 2.9 :!: 2.2 and 3.4 :!: 2.9 hours 
in adults and children. respectively. The mean peak FK 
506 plasma concentration achieved was 2.7 :: 2.2 ngtmL in 
adults and 2.6 :!: 2.2 ng/mL in children. Its mean trough 
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Fig 1. Plasma concentration vs time co-urse after IV (.) and oral 
administration (e) of FK 506 in an SST patient. 
plasma concentration was 0.9 :!: 0.6 ng/mL in adults and 
I.S ± 1.1 ng/mL in children. 
Maintenance Dose of FK 506 
The mean oral maintenance dose and trough level of FK 
506 at 2. 4. 6. 8. and 12 months posttransplant were higher 
in the SBT recipients compared with the OL T recipients. 
Pediatric patients appeared to require a higher dose of FK 
506 in order to obtain similar plasma concentrations seen 
in adults (Table I). 
DISCUSSION 
Kinetic parameters of FK 506 are comparable between 
SBT recipients and OL T recipients. Wide variations in its 
half-life. clearance. time to peak. peak levels. and bioavail-
ability remain a common problem in both OLT and SBT 
patients. Monitoring of FK 506 concentration. therefore. is 
very imponant. Despite these wide variations. however. 
SBT recipients absorb the drug and achieve adequate drug 
levels just as well as the OL T recipients. Children appear 
to require a higher dose of FK 506 based on a mg/kg/d basis 
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Table 1. 
AdUlts Children 
FK 506 Level FK 506 Level 
POS\1ransplanI 
FK 506 Oose (ngimUd) (nglmL) 
(mo) SeT OLT SST 
2 0.30:: 0.15 0.20:: 0.08 1.5 
4 0.22:: 0.14 0.17:: 0.08 1.1 
6 0.22:: 0.14 0.13:: 0.08 1.1 
8 0.20:: 0.14 0.13:: 0.08 1.2 
12 0.30:: 0.32 0.14:: 0.09 0.9 
Nole. Mean :!: SO ShOwn for FK 506 doses. Medians shown for FK 506 levels. 
to maintain a similar concentration in SBT just as reported 
for OL T recipients. ~ Because the incidence of rejection 
episodes in SBT recipients is much higher compared with 
the incidence of rejection in OLT recipients reported 
before,lo currently it is our practice to use a higher dose of 
FK 506 and maintain a higher FK 506 concentration in 
SBT recipients compared with OLT recipients. 
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